(Q39744811)

14 September 2017

title

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults (English)

1 reference

14 September 2017

1 reference

1 reference

Christine B Turley

1

1 reference

14 September 2017

Richard E Rupp

2

1 reference

14 September 2017

Casey Johnson

3

1 reference

14 September 2017

David N Taylor

4

1 reference

14 September 2017

Julie Wolfson

5

1 reference

14 September 2017

Lynda Tussey

6

1 reference

14 September 2017

Uma Kavita

7

1 reference

14 September 2017

Lawrence Stanberry

8

1 reference

14 September 2017

Alan Shaw

9

1 reference

14 September 2017

language of work or name

English

0 references

publication date

30 May 2011

1 reference

14 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 September 2017

volume

29

1 reference

14 September 2017

issue

32

1 reference

14 September 2017

page(s)

5145-5152

1 reference

Influenza vaccines for the future

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Prospects for universal influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Modified M2 proteins produce heterotypic immunity against influenza A virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Toll-like receptors and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

inferred from DOI database lookup

7 January 2021

based on heuristic

Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.041

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.05.041

1 reference

14 September 2017

1 reference